Stay updated on Efficacy Safety of Sintilimab IBI310 in EBV Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety of Sintilimab IBI310 in EBV Gastric Cancer Clinical Trial page.

Latest updates to the Efficacy Safety of Sintilimab IBI310 in EBV Gastric Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check88 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
- Check95 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
Stay in the know with updates to Efficacy Safety of Sintilimab IBI310 in EBV Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety of Sintilimab IBI310 in EBV Gastric Cancer Clinical Trial page.